Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Nasal polyps are painless, teardrop-shaped growths that form in your nose or sinuses. They’re most common where the sinuses near your eyes and cheekbones drain into your nose. Nasal polyps are not ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Researchers discuss contributors to nasal polyp development in children, as well as the risk of co-occuring conditions and current methods of treatment. Although rarely reported in childhood, nasal ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

The approval was supported by data from the phase 3 POLYP 1 (N=138) and POLYP 2 (N=127) trials evaluating the efficacy and safety of Xolair in adults with nasal polyps who had an inadequate response ...

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...

– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was the most used biologic. Allergists/immunologists prescribed the most biologics. Biologic ...

In Poland, the prevalence of chronic rhinosinusitis with nasal polyps was shown to be greater in men, elderly individuals, and those living in urban areas. Greater prevalence of chronic rhinosinusitis ...